The compound distributes preferentially to metabolically active organs, showing highest concentrations in the kidneys and liver, followed by the stomach wall, thymus, spleen, and intestines
Muller, B
Compounded versions of this dual agonist, often labeled GLP-1 GIP B12, add a third element: vitamin B12
In some embodiments, the otic formulation or composition comprises about 17% by weight of the poloxamer
Switching Injection Sites to Reduce GLP-1 Nausea Though there is no scientific evidence supporting the idea that changing the injection site reduces nausea, some patients have reported a possible reduction in nausea by rotating their injection sites
For general laboratory literature and research citations, consult the open access database on PubMed